JBCHEPHARM — J B Chemicals and Pharmaceuticals Balance Sheet
0.000.00%
- IN₹249.15bn
- IN₹245.85bn
- IN₹34.84bn
- 100
- 12
- 64
- 64
Annual balance sheet for J B Chemicals and Pharmaceuticals, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
R2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IAS | IAS | IAS | IAS | IAS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 3,657 | 6,976 | 578 | 2,692 | 4,596 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 4,089 | 4,849 | 7,557 | 7,948 | 8,602 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 10,732 | 15,526 | 12,749 | 15,280 | 18,533 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 5,842 | 5,697 | 5,668 | 5,764 | 6,349 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 18,206 | 22,381 | 26,074 | 35,539 | 39,941 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 3,133 | 3,453 | 3,837 | 5,544 | 8,682 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 3,851 | 4,284 | 4,733 | 10,735 | 10,708 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Unrealized Gain / Loss | |||||
Other Equity | |||||
Total Equity | 14,355 | 18,097 | 21,341 | 24,804 | 29,233 |
Total Liabilities & Shareholders' Equity | 18,206 | 22,381 | 26,074 | 35,539 | 39,941 |
Total Common Shares Outstanding |